JP2019527703A5 - - Google Patents

Download PDF

Info

Publication number
JP2019527703A5
JP2019527703A5 JP2019506145A JP2019506145A JP2019527703A5 JP 2019527703 A5 JP2019527703 A5 JP 2019527703A5 JP 2019506145 A JP2019506145 A JP 2019506145A JP 2019506145 A JP2019506145 A JP 2019506145A JP 2019527703 A5 JP2019527703 A5 JP 2019527703A5
Authority
JP
Japan
Prior art keywords
powder composition
pharmaceutical powder
intranasal pharmaceutical
particles
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019506145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527703A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/001121 external-priority patent/WO2018025089A2/en
Publication of JP2019527703A publication Critical patent/JP2019527703A/ja
Publication of JP2019527703A5 publication Critical patent/JP2019527703A5/ja
Priority to JP2022038221A priority Critical patent/JP7366178B2/ja
Pending legal-status Critical Current

Links

JP2019506145A 2016-08-05 2017-08-04 鼻腔内薬学的粉末組成物 Pending JP2019527703A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022038221A JP7366178B2 (ja) 2016-08-05 2022-03-11 鼻腔内薬学的粉末組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371298P 2016-08-05 2016-08-05
US62/371,298 2016-08-05
PCT/IB2017/001121 WO2018025089A2 (en) 2016-08-05 2017-08-04 Pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022038221A Division JP7366178B2 (ja) 2016-08-05 2022-03-11 鼻腔内薬学的粉末組成物

Publications (2)

Publication Number Publication Date
JP2019527703A JP2019527703A (ja) 2019-10-03
JP2019527703A5 true JP2019527703A5 (cg-RX-API-DMAC7.html) 2020-09-10

Family

ID=60084012

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019506145A Pending JP2019527703A (ja) 2016-08-05 2017-08-04 鼻腔内薬学的粉末組成物
JP2022038221A Active JP7366178B2 (ja) 2016-08-05 2022-03-11 鼻腔内薬学的粉末組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022038221A Active JP7366178B2 (ja) 2016-08-05 2022-03-11 鼻腔内薬学的粉末組成物

Country Status (9)

Country Link
US (2) US10792253B2 (cg-RX-API-DMAC7.html)
EP (2) EP3493789A2 (cg-RX-API-DMAC7.html)
JP (2) JP2019527703A (cg-RX-API-DMAC7.html)
KR (1) KR102489453B1 (cg-RX-API-DMAC7.html)
CN (1) CN109640947A (cg-RX-API-DMAC7.html)
AU (1) AU2017307306B2 (cg-RX-API-DMAC7.html)
CA (1) CA3030359A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019001313A (cg-RX-API-DMAC7.html)
WO (1) WO2018025089A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049059B1 (en) 2013-09-24 2021-11-03 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
US20200297734A1 (en) 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20190142841A1 (en) * 2015-06-19 2019-05-16 Harrow Health, Inc. Pharmaceutical compositions and methods for anesthesiological applications
EP3341059B1 (en) 2015-09-10 2022-03-02 Impel NeuroPharma Inc. In-line nasal delivery device
CA3030359A1 (en) * 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
BR112020013744A8 (pt) 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão
CA3122396A1 (en) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
CN111346078B (zh) * 2018-12-21 2022-06-10 宜昌人福药业有限责任公司 一种他喷他多或其药学上可接受的盐经鼻粘膜给药的药物组合物及其制备方法和应用
JP7900916B2 (ja) * 2019-05-16 2026-08-05 株式会社新日本科学 経鼻投与用の粉末製剤及びその製造方法
CN114269712A (zh) * 2019-05-28 2022-04-01 夏洛特-梅克伦堡医院管理局D/B/A艾奇恩健康 制备核糖醇的组合物和方法
CA3166250A1 (en) 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
EP4121083A4 (en) * 2020-03-18 2023-11-29 Cara Therapeutics, Inc. OLIGOSACCHARIDE FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS
CN121265577A (zh) 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
KR102563646B1 (ko) * 2021-04-06 2023-08-07 (주)메디코어 비강 세정용 분말 조성물의 제조방법 및 그에 따라 제조된 비강 세정용 분말 조성물
WO2022224030A1 (en) * 2021-04-20 2022-10-27 Sava Healthcare Ltd Dry powder inhalation (dpi) formulation
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20260232581A1 (en) * 2022-09-28 2026-08-13 Board Of Regents, The University Of Texas System Respiratory dry powder delivery
CN115737568A (zh) * 2022-11-24 2023-03-07 东南大学 一种利培酮鼻用粉雾剂及其制备方法
EP4626438A2 (en) * 2022-12-01 2025-10-08 Pinata Holdings Inc. Inhalable hormone receptor agonist formulations
CN117003689A (zh) * 2023-09-28 2023-11-07 成都瑞尔医药科技有限公司 一种碘解磷定的晶型及其制备方法
WO2025101272A1 (en) * 2023-11-11 2025-05-15 Css Pharma L.L.C. Pharmaceutical composition for the acute treatment of migraine and other forms of headache

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
SE9604486D0 (sv) * 1996-12-05 1996-12-05 Astra Ab Novel formulation
CA2341732C (en) * 1998-08-26 2008-08-19 Teijin Limited Powder composition for nasal administration
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
CA2583794C (en) * 2004-10-11 2015-05-26 Nasaleze Ppm Limited Compositions for intranasal administration
EP1829549A1 (en) * 2004-12-17 2007-09-05 Ono Pharmaceutical Co., Ltd. Amorphous composition
ES2652415T3 (es) * 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
US20110077272A1 (en) 2008-02-01 2011-03-31 Vectura Limited Pulmonary formulations of triptans
CA2734646C (en) 2008-08-20 2016-06-28 James W. Mcginity Hot-melt extrusion of modified release multi-particulates
KR20160148041A (ko) 2009-04-24 2016-12-23 아이슈티카 피티와이 리미티드 캅셀화된 나노입자의 상업적 규모의 생산
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
ES2659761T3 (es) 2011-01-31 2018-03-19 Shin Nippon Biomedical Laboratories, Ltd. Dispositivos de administración intranasal
EP2601973A1 (en) 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
AU2014226192B2 (en) 2013-03-04 2018-07-26 Besins Healthcare Luxembourg Sarl Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
EP3049059B1 (en) 2013-09-24 2021-11-03 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
RU2570092C2 (ru) 2013-09-30 2015-12-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Петрозаводский государственный университет" Способ выявления различий структурного состояния целлюлозы
CA3030359A1 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions

Similar Documents

Publication Publication Date Title
JP7366178B2 (ja) 鼻腔内薬学的粉末組成物
US9101539B2 (en) Intranasal pharmaceutical compositions with improved pharmacokinetics
Luinstra et al. A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods
AU2014253115B2 (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
JP2005520799A (ja) 即時放出型の微細化された医薬または栄養補助食品の粉末
AU2021200503B2 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
CN101677954A (zh) 治疗性施用dhe用于快速减轻偏头痛而使副作用分布最小化的方法
WO2019036503A1 (en) CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
WO2022127092A1 (zh) 一种川丁特罗吸入粉雾剂及其制备方法和应用
Khatri et al. Nasal in-situ gel: an approach to enhance therapeutic benefits of the drug
JP2017530987A (ja) ブデソニド及びホルモテロールを含有する医薬組成物
BR112019002371B1 (pt) Composição farmacêutica intranasal em pó compreendendo partículas secas por aspersão, uso da referida composição para tratar ou prevenir dor de cabeça, dispositivo contendo a referida composição e método de preparo da referida composição farmacêutica
BR112017007182B1 (pt) Composição farmacêutica para uso inalatório na forma de pó e kit compreendendo a referida composição